Sarcoma patients share their experience on returning chemotherapy

NCT ID NCT06050434

Terminated Knowledge-focused Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 15, 2026 · Updated 25 times

Summary

This study aimed to learn about the symptoms, side effects, and quality of life in people with soft tissue sarcoma who were restarting a chemotherapy drug called trabectedin. Researchers planned to follow 7 patients who had previously taken trabectedin but stopped for reasons like side effects or disease progression. The goal was to gather patient feedback to better understand the real-world experience of this treatment approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Frankfurt Universitätsklinikum

Frankfurt am Main, Germany
HELIOS KLinikum Bad Saarow

Bad Saarow, Germany
HELIOS Klinikum Berlin Buch

Berlin, Germany
Uniklinikum Leipzig

Leipzig, Germany
Universitätsklinikum Tübingen

Tübingen, Germany
Universitätsmedizin Greifswald

Greifswald, Germany
Universitätsmedizin Göttingen

Göttingen, Germany
Universitätsmedizin Mainz

Mainz, Germany
Westfälische Wilhelms-Universität Münster

Münster, Germany

Conditions

Explore the condition pages connected to this study.

SOFT TISSUE SARCOMA